EUCTR2011-002944-28-DE进行中（未招募）不适用
A phase 2, multi-national, multi-centre, double masked,randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Subject is at least 18 years of age inclusive, at the time of signing the informed consent
- •1. A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]
- •Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or Investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use
- •contraception until follow up visit
- •2. Diagnosis of diabetes mellitus (type 1 or type 2)
- •3. Confirmation of DME in the study eye by investigator-determined fluorescein angiography
- •4. Retinal thickening (diabetic macular edema) involving the centre of the fovea in the study eye as defined by investigator-determined SD-OCT central subfield thickness > 330 microns for Heidelberg Spectralis and >310 for Zeiss Cirrus; if both eyes are eligible, the eye with the greater OCT centre subfield score is selected as the study eye.
- •5. Best corrected visual acuity score of 78-24 letters (Snellen equivalent ~20/32 to 20/320) in the study eye
- •6. Subject is willing and able to return for all study visits, and is willing and able to comply with all protocol requirements and procedures
- •7. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria
- •1. Additional eye disease in the study eye that could compromise assessment of BCVA
- •or imaging of the posterior pole by fundus photography, fluorescein angiography, or
- •spectral domain OCT, or is likely to require intervention during the ~4 month study
- •(e.g. cataract, glaucoma with documented visual field loss, ischemic optic
- •neuropathy, retinitis pigmentosa)
- •2. Active proliferative diabetic retinopathy in the study eye
- •3. Ischemic maculopathy on fluorescein angiography defined as a total area of capillary
- •loss greater than 2 disc areas (> 5mm2) within the ETDRS macular grid or a foveal
- •avascular zone greatest linear diameter of > 1000 microns
- •4. History of choroidal neovascularization in the study eye, or current choroidal
- •neovascularization in the fellow eye requiring treatment
- •5. Intraocular surgery in the study eye within 3 months of dosing
- •6. Laser photocoagulation in the study eye within 3 months of dosing
- •7. Use of intravitreal ranibizumab in the study eye within 90 days of dosing
- •8. Use of intravitreal bevacizumab in the study eye within 180 days of dosing
- •9. Use of intraocular steroids in the study eye within 180 days of dosing
- •10. Use of intravitreal bevacizumab in the fellow eye or expected need for intravitreal
- •bevacizumab in the fellow eye during the course of the study
- •11. Best-corrected visual acuity score by electronic ETDRS < 56 letters in the fellow eye
- •at screening
- •12. Use of any systemically administered anti-angiogenic agent (e.g., bevacizumab,
- •sunitinib, cetuximab, sorafenib, pazopanib), approved or investigational, within 6
- •months of dosing
- •13. Evidence of vitreomacular traction as determined by the Investigator
- •14. Uncontrolled intraocular pressure >22 mmHg in the study eye despite treatment with
- •glaucoma medication
- •15. Within 6 months prior to the Screening Visit, use of medications known to be toxic
- •to the retina, lens or optic nerve (e.g. desferoximine,chloroquine/hydrochloroquine,
- •chlorpromazine, phenothiazines, tamoxifen, and ethambutol)
- •Non-ocular
- •16. Uncontrolled diabetes as indicated by HbA1c >10% at screening
- •17. Evidence of clinical instability or abnormal clinical laboratory findings prior to
- •randomisation that, in the opinion of the Investigator, makes the subject unsuitable
- •for the study
- •18. Current liver disease, known hepatic or biliary abnormalities (with the exception of
- •Gilbert’s syndrome or asymptomatic gallstones) or evidence of abnormal liver
- •function tests [total bilirubin or alkaline phosphatase >1.5 x upper limit of normal
- •(ULN); or ALT or AST >2.5 x ULN] or other hepatic abnormalities that in the
- •opinion of the Investigator would preclude the subject from participation in the
- •19. Severe renal impairment (e.g., patients with an estimated glomular filtration rate
- •(GFR) <30 mL/min/1.73m2 or receiving chronic dialysis) or history of nephrectomy
- •or kidney transplant (regardless of renal function)
- •20. Poorly controlled hypertension despite lifestyle modifications and
- •pharmacotherapy; systolic blood pressure >160mmHg or diastolic blood pressure
- •>110mmHg (mean of 3 measurements according to protocol-specified conditions)
- •21. Current severe heart failure (New York Heart Association class III or IV)
- •22. QTcF > 480msec in any subject including those with Bundle Branch Block
- •23. Severe asthma that is poorly controlled on pharmacotherapy
研究者
相似试验
已完成
2 期
A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement (DM2115403)macular edema10015917NL-OMON35596GlaxoSmithKline BV10
进行中（未招募）
不适用
A 3 month Study of Darapladib to Treat Diabetic Macular Edema (DME).Diabetic macular edema with centre involvementMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersEUCTR2011-002944-28-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.60
进行中（未招募）
1 期
A 3 month Study of Darapladib to Treat Diabetic Macular Edema (DME).MedDRA version: 14.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersDiabetic macular edema with centre involvementEUCTR2011-002944-28-DKGlaxoSmithKline Research & Development Limited54
进行中（未招募）
不适用
A 3 month Study of Darapladib to Treat Diabetic Macular Edema (DME).Diabetic macular edema with centre involvementMedDRA version: 14.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersEUCTR2011-002944-28-NLGlaxoSmithKline Research & Development Limited54
进行中（未招募）
不适用
A study to compare the single administration of a product called CHF 1535 (two medicines together for the treatment of asthma) and the same two single medicines, measuring the air contained in the lungs in asthmatic childreAsthmaEUCTR2011-002060-24-PLChiesi Farmaceutici SpA100